BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 21637290)

  • 1. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
    Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
    Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival.
    Foggetti G; Ottaggio L; Russo D; Mazzitelli C; Monti P; Degan P; Miele M; Fronza G; Menichini P
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30745455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
    Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
    Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
    Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
    Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
    Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
    J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.
    Pai JT; Hsu CY; Hua KT; Yu SY; Huang CY; Chen CN; Liao CH; Weng MS
    Molecules; 2015 May; 20(5):8000-19. PubMed ID: 25946558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis.
    Ryu HW; Shin DH; Lee DH; Choi J; Han G; Lee KY; Kwon SH
    Cancer Lett; 2017 Apr; 391():162-171. PubMed ID: 28153791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation.
    Seo SK; Hwang CS; Choe TB; Hong SI; Yi JY; Hwang SG; Lee HG; Oh ST; Lee YH; Park IC
    Oncotarget; 2015 Sep; 6(28):26528-40. PubMed ID: 25605253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
    Yerbes R; López-Rivas A
    Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
    FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
    Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T
    Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
    Meng Q; Chen X; Sun L; Zhao C; Sui G; Cai L
    Mol Cell Biochem; 2011 Feb; 348(1-2):165-71. PubMed ID: 21082217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
    Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
    Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
    Palani CD; Beck JF; Sonnemann J
    Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
    Hutt DM; Roth DM; Vignaud H; Cullin C; Bouchecareilh M
    PLoS One; 2014; 9(8):e106224. PubMed ID: 25166596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells.
    Park S; Park JA; Kim YE; Song S; Kwon HJ; Lee Y
    Cell Stress Chaperones; 2015 Jan; 20(1):149-57. PubMed ID: 25119188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.